HUE047454T2 - CXC kemokin receptor 4 (CXCR4) antagonista polipeptid - Google Patents

CXC kemokin receptor 4 (CXCR4) antagonista polipeptid

Info

Publication number
HUE047454T2
HUE047454T2 HUE17192177A HUE17192177A HUE047454T2 HU E047454 T2 HUE047454 T2 HU E047454T2 HU E17192177 A HUE17192177 A HU E17192177A HU E17192177 A HUE17192177 A HU E17192177A HU E047454 T2 HUE047454 T2 HU E047454T2
Authority
HU
Hungary
Prior art keywords
cxcr4
chemokine receptor
cxc chemokine
antagonistic polypeptide
antagonistic
Prior art date
Application number
HUE17192177A
Other languages
English (en)
Inventor
Wolf-Georg Forssmann
Frank Kirchhoff
Jan Muench
Ludger Ständker
Original Assignee
Pharis Biotec Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharis Biotec Gmbh filed Critical Pharis Biotec Gmbh
Publication of HUE047454T2 publication Critical patent/HUE047454T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
HUE17192177A 2007-07-03 2008-07-03 CXC kemokin receptor 4 (CXCR4) antagonista polipeptid HUE047454T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007030904A DE102007030904A1 (de) 2007-07-03 2007-07-03 Humanes zirkulierendes antivirales Albumin-Fragment (ALB-408) und seine Verwendung

Publications (1)

Publication Number Publication Date
HUE047454T2 true HUE047454T2 (hu) 2020-04-28

Family

ID=39760841

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE17192177A HUE047454T2 (hu) 2007-07-03 2008-07-03 CXC kemokin receptor 4 (CXCR4) antagonista polipeptid
HUE08774691A HUE037931T2 (hu) 2007-07-03 2008-07-03 CXC kemokin receptor 4 (CXCR4) antagonista polipeptid

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE08774691A HUE037931T2 (hu) 2007-07-03 2008-07-03 CXC kemokin receptor 4 (CXCR4) antagonista polipeptid

Country Status (12)

Country Link
US (1) US9045563B2 (hu)
EP (2) EP3275894B1 (hu)
JP (2) JP2010531655A (hu)
CN (1) CN101730709B (hu)
CA (2) CA2968054C (hu)
DE (1) DE102007030904A1 (hu)
DK (2) DK3275894T3 (hu)
ES (2) ES2655289T3 (hu)
HU (2) HUE047454T2 (hu)
PL (2) PL3275894T3 (hu)
PT (2) PT2162462T (hu)
WO (1) WO2009004054A2 (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
EP2799877A1 (en) 2013-05-03 2014-11-05 Universität Ulm Process for diagnosing a human subject with diseases affecting the kidneys, or at risk of acquiring diseases affecting the kidneys
ES2699576T3 (es) * 2013-06-12 2019-02-11 Pharis Biotec Gmbh Péptidos con actividades antagonistas contra CXCR4 natural
CN104292302B (zh) * 2013-07-16 2018-05-04 国家纳米科学中心 一种增强肿瘤细胞对抗肿瘤药物敏感性的多肽及其应用
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
WO2016013828A1 (ko) * 2014-07-21 2016-01-28 연세대학교 산학협력단 황산화된 더피 케모카인 수용체의 세포 외 도메인 1 변이체 및 이의 용도
WO2016079143A1 (de) 2014-11-17 2016-05-26 Pharis Biotec Gmbh Inhibitor der viralen hepatitis c infektion
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
WO2018075830A1 (en) 2016-10-19 2018-04-26 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
WO2019048666A1 (en) 2017-09-08 2019-03-14 Neopep Pharma Gmbh & Co. Kg POLYPEPTIDES FOR THE TREATMENT OF DISEASES
AU2018385759B2 (en) 2017-12-14 2021-10-21 Flodesign Sonics, Inc. Acoustic transducer driver and controller
BR112021008797A2 (pt) * 2018-11-09 2021-08-31 Neopep Pharma Gmbh & Co. Kg Polipeptídeos para o tratamento de síndromes de estresse, imunorreação e derrame
EP3872084A1 (en) 2020-02-27 2021-09-01 Universität Ulm Epi-x4 based peptides and derivatives thereof
WO2023099725A1 (de) * 2021-12-02 2023-06-08 Pharis Biotec Gmbh Pharmazeutische zubereitung enthaltend eine mischung eines natriuretischen peptids (anp) und eines peptidischen hemmstoffs des cxcr4-rezeptors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1028977B1 (de) * 1997-09-16 2003-11-26 FORSSMANN, Wolf-Georg Bifidogene peptide und deren verwendung
CN1195779C (zh) * 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 抗人卵巢癌抗人cd3双特异性抗体
GB0217347D0 (en) * 2002-07-26 2002-09-04 Univ Edinburgh Novel albumins
WO2007097923A2 (en) * 2006-02-20 2007-08-30 Phylogica Limited Method of constructing and screening libraries of peptide structures
CN1872879B (zh) * 2006-06-29 2011-09-14 孙晗笑 来源于病毒巨噬细胞炎性蛋白的cxcr4受体拮抗活性多肽及其应用
MX2009008230A (es) * 2007-01-30 2010-03-08 Epivax Inc Epitopes de celulas t reguladoras, composiciones y usos para los mismos.

Also Published As

Publication number Publication date
EP2162462B1 (en) 2017-10-25
PT3275894T (pt) 2020-02-06
ES2655289T3 (es) 2018-02-19
PL2162462T3 (pl) 2018-03-30
CA2691061C (en) 2017-07-11
JP5941497B2 (ja) 2016-06-29
ES2770361T3 (es) 2020-07-01
WO2009004054A2 (en) 2009-01-08
CN101730709A (zh) 2010-06-09
WO2009004054A8 (en) 2017-04-06
EP3275894B1 (en) 2019-11-13
WO2009004054A3 (en) 2009-02-26
EP3275894A1 (en) 2018-01-31
PL3275894T3 (pl) 2020-07-13
DE102007030904A1 (de) 2009-02-05
CA2968054C (en) 2022-06-14
CN101730709B (zh) 2013-06-12
EP2162462A2 (en) 2010-03-17
CA2968054A1 (en) 2009-01-08
JP2010531655A (ja) 2010-09-30
DK3275894T3 (en) 2020-02-03
DK2162462T3 (da) 2018-01-29
JP2014209914A (ja) 2014-11-13
HUE037931T2 (hu) 2018-09-28
PT2162462T (pt) 2018-01-31
US9045563B2 (en) 2015-06-02
CA2691061A1 (en) 2009-01-08
US20130029902A1 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
PT3275894T (pt) Um polipéptido antagonístico do recetor 4 de quimiocina cxc (cxcr4)
TWI346553B (en) Chemokine receptor antagonists
EP2099454A4 (en) AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS
EP1871752A4 (en) ANTAGONISTS OF THE AMIDOPROPOXYPHENYLOREXIN RECEPTOR
EP1613613A4 (en) CXCR4-CHEMOKIN RECEPTOR BINDING COMPOUNDS
TWI341198B (en) Hydroisoindoline tachykinin receptor antagonists
HK1141474A1 (en) Cyclic peptide cxcr4 antagonists
IL192426A0 (en) Prokineticin 2 receptor antagonists
IL187424A0 (en) C5a RECEPTOR ANTAGONISTS
EP1924265A4 (en) COMPOUNDS BINDING TO CHEMOKINE RECEPTORS
IL190686A0 (en) Il-21 receptor antagonists
IL192424A0 (en) Prokineticin 1 receptor antagonists
HUP0600858A2 (en) Piperizinyilpiperidine derivatives as chemokine receptor antagonists
IL184278A0 (en) C5a RECEPTOR ANTAGONISTS
EP2170064A4 (en) 6,5-pyrrolopiperidine tachykinin receptor antagonists
EP1896023A4 (en) CHEMOKINE RECEPTOR BINDING COMPOUNDS
ZA200609461B (en) High affinity NY-ESO T cell receptor
IL205749A0 (en) Modified il-4 mutein receptor antagonists
EP1898905A4 (en) ANTAGONISTS OF TACHYKININ HYDRO-ISO-INDOLIC RECEPTORS
AP2008004537A0 (en) Muscarinic receptor antagonists
ZA200605574B (en) Hydroisoindoline tachykinin receptor antagonists
ZA200806223B (en) Muscarinic receptor antagonists
GB0526000D0 (en) Cytokine receptor
ZA200608369B (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists
GB0419643D0 (en) High affinity ny-eso t cell receptors